The meeting covered several aspects of currently used immunosuppressive drugs, but focused on tolerance induction strategies in the treatment of both allograft rejection and autoimmune diseases. Topics discussed included: clinical trials with anti-CD3 in recently-diagnosed insulin-dependent diabetes mellitus (IDDM) patients; Tr1 cells in bone-marrow transplantation; and, 1 alpha,25-dihydroxyvitamin D3-associated with mycophenolate mofetil and anti-CD25 in islet transplantation. In addition, malononitrilamides, an emerging class of novel immunosuppressants, were discussed in depth.